

The evolution of brain death criteria: From historical foundations to modern standards

Joseph Varon¹, Najia Hussaini², Simon Nanlohy³

Abstract

The concept of brain death, or death by neurologic criteria (BD/DNC), marks a transformative shift in defining death, moving from traditional cardiorespiratory cessation to neurological criteria driven by advancements in critical care and organ transplantation. This manuscript traces the evolution from 1950s European observations and the 1968 Harvard Committee report to the 1981 Uniform Determination of Death Act (UDDA) and the 2023 AAN/AAP/CNS/SCCM

consensus guidelines. It explores historical milestones, modern clinical protocols, ancillary testing, and ongoing controversies, including the whole brain versus brainstem debate, ethical issues in organ donation, and cultural and religious objections. Emphasizing scientific rigor and interdisciplinary perspectives, this review advocates for global standardization while addressing critiques that brain death conflates dying with death.

Keywords: Brain death criteria, cardiopulmonary resuscitation, coma, electroencephalogram, brain perfusion.

Introduction

Historical foundations

The determination of death has historically relied on the irreversible cessation of heartbeat and breathing, a standard rooted in observable physiological signs. The mid-20th-century introduction of mechanical ventilation and cardiopulmonary resuscitation dis-

rupted this paradigm, enabling the sustainment of vital functions in patients with catastrophic brain injuries. (1) This technological shift necessitated a redefinition of death, giving rise to the concept of brain death, or death by neurologic criteria (BD/DNC), which fundamentally altered medical, legal, and ethical frameworks. (2)

In the 1950s, European clinicians laid the groundwork for this development. In 1952, Danish anesthesiologist Bjørn Ibsen pioneered the use of positive pressure ventilation to rescue a patient with poliomyelitis, significantly reducing mortality from respiratory failure. (3) By 1953, Riishede and Ethelberg documented absent intracranial vessel filling in comatose ventilated patients via angiography, attributing it to elevated intracranial pressure from severe brain injury. (3) In 1959, French neurologists Pierre Mollaret and Maurice Goulon introduced the concept of "coma dépassé," describing apneic, areflexic patients on ventilators with absent brainstem function and no electroencephalogram (EEG) activity. (4,5) These cases, characterized by irreversible brain damage, marked the conceptual genesis of brain death, independent of organ transplantation motives. (3)

The formalization of brain death criteria occurred in

¹Independent Medical Alliance; The University of Houston College of Medicine; Dorrington Medical Associates; Caribbean Medical University

²Dorrington Medical Associates, PA, USA

³Critical Care Department, Eka Hospital Bekasi, Bekasi 17214, Indonesia

Address for correspondence:

Joseph Varon, MD, FACP, FCCP, FCCM, FRSM
2219 Dorrington Street, Houston, Texas 77030, USA
Tel: +1-713-669-1670
Fax: +1-713-669-1671
Email: jvaron@imahealth.org

1968 with the Harvard Ad Hoc Committee's report, "A Definition of Irreversible Coma," which defined brain death as the absence of brain function, including unreceptivity, unresponsivity, lack of spontaneous breathing, no muscular movements, absent reflexes, and a flat EEG. (6,7) Driven by ethical concerns about prolonged life support in irreversible coma and the emerging need for organ procurement, the Harvard criteria shifted the focus to the brain as the central integrator of life, a concept later refined by neurologist James Bernat. (8,9) The report emphasized clinical and EEG-based assessments, although it acknowledged diagnostic challenges, such as distinguishing between coma and reversible states. (6)

The 1970s brought refinements. The 1971 Minnesota study by Mohandas and Chou proposed that clinical judgment could suffice without a mandatory EEG, noting that residual brain activity in some cases did not negate death. (10) This pragmatic shift made EEG optional, but sparked concerns about diagnostic accuracy, as EEGs could miss subcortical activity. (11) In 1981, the US President's Commission for the Study of Ethical Problems in Medicine endorsed these criteria, leading to the Uniform Determination of Death Act (UDDA), which legally defined death as the irreversible cessation of all brain functions (including those of the brainstem) or cardiorespiratory functions. (7,12) The UDDA provided a unified legal framework, influencing global standards and solidifying brain death as a medical and legal construct. (13)

Philosophically, brain death posits the brain as essential for personhood and consciousness, aligning with the whole-brain formulation dominant in the US, which requires catastrophic injury to all brain structures. (7) In contrast, the UK adopted a brainstem death model, arguing that brainstem destruction alone is sufficient, as it controls vital functions such as respiration. (14) A less accepted higher-brain model, focusing on cortical loss, conflicts with apnea requirements and remains marginal. (7) Early criticisms emerged, with some arguing brain death was a construct to facilitate organ donation rather than a true equivalent of death. (15) Persistent neuroendocrine functions, such as antidiuretic hormone (ADH) secretion, in brain-dead patients challenged the "all functions" criterion, fueling philosophical and scientific debates. (15)

Historical development

The 1980s and 1990s refined brain death criteria through the development of evidence-based protocols. The American Academy of Neurology (AAN) issued guidelines in 1995 for adults, emphasizing

bedside tests such as brainstem reflexes (pupillary, corneal, oculocephalic, oculo-vestibular, gag, and cough) and apnea testing, while relegating ancillary tests like EEG to optional status when clinical exams were conclusive. (7,16) Pediatric guidelines emerged in 1987, updated in 2011 by the American Academy of Pediatrics (AAP), the Society of Critical Care Medicine (SCCM), and the Child Neurology Society (CNS), addressing developmental differences such as immature brainstem responses in infants. (17,18) These updates required two examinations for children to ensure accuracy, reflecting caution due to physiological variability. (18)

Transatlantic differences solidified during this period. The US adhered to whole-brain death, requiring evidence of cessation across all brain regions, including the brainstem, to minimize misdiagnosis. (14) The UK's brainstem death model, formalized in the 1970s, prioritized the loss of brainstem function, arguing that it was sufficient, as the brainstem governs respiration and consciousness. (14) This divide, rooted in the debates of the 1970s and 1980s, reflected differing priorities: the US emphasis on comprehensive brain failure versus the UK focus on functional essentials. (14) Critics noted that brainstem death could miss residual cortical activity, while whole-brain criteria risked overcomplicating diagnostics. (19)

Globally, variability persisted. Japan initially resisted whole-brain criteria due to cultural beliefs valuing somatic integrity, only adopting them in the 1990s with strict conditions for organ donation. (20) In India, brain death criteria aligned with Western models but faced implementation challenges due to resource limitations and cultural skepticism. (21) These East-West differences underscored how advancements in neuroscience, critical care innovations, and transplantation needs drove the evolution of criteria. (22)

The 2000s introduced further rigor. The AAN's 2010 adult guidelines addressed confounders like hypothermia (<36 °C), hypotension, and sedative effects, recommending at least five half-lives for drug clearance before testing. (7,23) Apnea testing was standardized, targeting a partial pressure of carbon dioxide in arterial blood (PaCO₂) of ≥60 mmHg to confirm the absence of respiratory drive, with protocols in place to manage complications such as hypoxia. (7) Controversies arose with cases of "chronic brain death," where patients survived weeks with residual functions (e.g., hypothalamic activity), as meta-analyzed by Shewmon in 1998. (24) These cases questioned the irreversibility and integration criteria, suggesting that the body could retain some coordinated functions without a func-

tioning brain. (15)

The 2020 World Brain Death Project aimed to achieve a global consensus, documenting protocols in 61% of countries, but highlighted persistent variability in apnea testing, ancillary test use, and legal definitions. (25) Efforts to standardize included recommendations for training and documentation to reduce diagnostic errors. (26)

Modern criteria and updates

Modern brain death determination prioritizes standardization to ensure reliability and public trust. (27) The 2023 AAN/AAP/CNS/SCCM consensus guidelines unified the adult and pediatric protocols, updating the 2010 adult and 2011 pediatric versions. (28,29) These guidelines emphasize a structured approach: identifying an irreversible brain injury cause (e.g., trauma, anoxia), excluding confounders (e.g., hypothermia $<36^{\circ}\text{C}$, systolic blood pressure [BP] <100 mmHg in adults, or central nervous system [CNS] depressants), and conducting a clinical exam assessing coma, absent brainstem reflexes, and apnea. (7)

The clinical exam tests for unresponsiveness, absent pupillary response to light, corneal reflex, oculocephalic and oculovestibular reflexes, gag reflex, and cough, ensuring the absence of brainstem activity. (7) Apnea testing, critical for confirming the absence of respiratory drive, targets a PaCO_2 of ≥ 60 mmHg and a pH of <7.30 , with adaptations for extracorporeal membrane oxygenation (ECMO) patients by minimizing sweep gas flow to prevent CO_2 washout. (5,7) Ancillary tests, such as EEG, cerebral blood flow studies (e.g., computed tomography [CT] angiography, transcranial Doppler), or single-photon emission computed tomography (SPECT), are reserved for cases where clinical exams are inconclusive due to confounders or injuries precluding reflex testing. (7)

Key updates in 2023 include eliminating mandatory waiting periods between exams for adults (one exam is sufficient), retaining two exams for pediatrics, and specifying pediatric criteria (e.g., applicable to age ≥ 37 weeks' gestation, with SPECT preferred for ancillary testing). (7,28) Post-cardiac arrest patients undergoing targeted temperature management require a 24-hour wait post-rewarming to avoid false positives. (7) These changes reflect evidence from studies showing high diagnostic accuracy when protocols are followed, with no documented false positives since the 1960s when guidelines are adhered to. (3,30)

Controversies persist, particularly regarding the prevention of false positives and accommodating family objections. In some Islamic countries, like

Egypt, brain death lacks consensus, with scholars divided on equating it to death for organ donation versus rejecting it outright due to residual somatic functions. (5) Educational initiatives and advancements in neuromonitoring, such as continuous EEG or intracranial pressure monitoring, are proposed to enhance diagnostic precision and public acceptance. (3)

Controversies and ethical considerations

Despite robust validation, brain death remains contentious. Since the 1960s, no false positives have been reported when guidelines are strictly followed. Yet, critics like Shewmon argue that persistent integrative functions (e.g., hypothalamic regulation) undermine the equivalence of brain death with death. (15,30) These functions, such as ADH secretion or temperature regulation, suggest that the body retains some level of coordination, challenging the whole-brain death criterion. (24)

Religious perspectives complicate acceptance. Christian anthropology, for instance, defines death as the separation of soul and body, conflicting with residual somatic activity in brain-dead patients. (15) Islamic and Jewish scholars debate whether brain death fulfills theological definitions of death, with some accepting it for organ donation and others requiring cardiorespiratory cessation. (31) These views influence legal frameworks, as seen in Germany, where brain death is tied to transplantation law, creating ethical asymmetry. (3)

The link to organ donation fuels skepticism. Critics argue that brain death was developed to facilitate transplantation, raising concerns about premature declarations to procure organs. (32) The "dead donor rule," requiring death before organ retrieval, is debated, with some proposing donation after circulatory death as an alternative, though this introduces its own ethical challenges. (33,34) Public misunderstanding, exacerbated by media portrayals, further complicates acceptance, necessitating improved education and awareness. (35)

Legal inconsistencies add complexity. In the US, the UDDA standardizes brain death, but state variations in implementation (e.g., accommodation for religious objections) create disparities. (36) Globally, 39% of countries lack formal brain death protocols, and variations in apnea testing or ancillary test requirements hinder uniformity. (25) Proposals for global standards, such as those from the World Brain Death Project, aim to address these gaps but face cultural and logistical barriers. (25)

Global perspectives

The evolution of brain death criteria reflects diverse

global practices (**Figure 1**). In Europe, the UK's brainstem death model contrasts with Germany's whole-brain approach, which requires extensive ancillary testing due to legal ties to transplantation. (3,14) In Asia, Japan's delayed acceptance of brain death until 1997 stemmed from cultural reverence for the body, with ongoing restrictions limiting organ donation. (20) India's Transplantation of Human Organs Act (1994) adopted brain death but struggles with inconsistent application due to limited critical care resources. (21)

In Africa, brain death protocols are sparse, with South Africa being an exception, adopting whole-brain criteria aligned with Western models. (37) In Islamic countries, fatwas vary: Saudi Arabia accepts brain death for organ donation, while Egypt's lack of consensus delays implementation. (5) These disparities highlight the interplay of medical, cultural, and religious factors, with 61% of countries having some protocol but no universal standard. (25)

The World Brain Death Project's 2020 recommendations advocate for minimum criteria, including a clinical examination, apnea testing, and optional ancillary tests, tailored to resource availability. (25) Challenges include training clinicians, standardizing documentation, and addressing public skepticism, particularly in regions with low trust in the medical system. (38) Future global harmonization requires striking a balance between scientific rigor and cultural sensitivity, potentially through the development of international guidelines and education campaigns. (39)

Future directions

Advancements in neuromonitoring, such as real-time EEG or cerebral blood flow imaging, promise to enhance diagnostic precision, reducing reliance on clinical exams in complex cases. (3) Artificial in-

telligence could analyze multimodal data (e.g., EEG, CT angiography) to predict irreversibility, although ethical concerns about automation in death determination persist. (40) Public education is critical to counter misinformation, as studies show media portrayals often confuse brain death with coma, undermining trust. (35)

Policy efforts should focus on global standardization, addressing variability in apnea testing (e.g., PaCO₂ thresholds) and the availability of ancillary tests. (25) Ethical frameworks must evolve to address religious objections and accommodate family requests, balancing individual beliefs with the medical urgency of organ donation. Research into "chronic brain death" cases could clarify the biological boundaries of death, informing criteria updates. (24) Ultimately, interdisciplinary collaboration among neurologists, ethicists, policymakers, and religious leaders is essential to align brain death definitions with scientific and societal values.


Conclusions

The evolution of brain death criteria reflects a dynamic interplay of medical innovation, ethical debate, and cultural diversity. From the 1950s' technological breakthroughs to the 2023 consensus guidelines, brain death has reshaped end-of-life care and organ transplantation. Persistent controversies—philosophical, religious, and legal—underscore the need for ongoing refinement and global dialogue to ensure criteria are scientifically robust and culturally inclusive. This manuscript, through historical analysis and modern insights, advocates for standardized protocols and education to bridge divides and uphold trust in brain death determination.

Acknowledgment

The authors disclose no conflicts of interest.

Figure 1. Historical evolution of brain death criteria



References

1. Daroff RB. The historical evolution of brain death from former definitions of death: the Harvard criteria to the present [Internet]. 2007 [cited 2025 Aug 31]. Available from: <https://www.pas.va/content/dam/casinapi-oiv/pas/pdf-volumi/scripta-varia/sv110/sv110-daroff.pdf>
2. Truog RD, Pope TM, Jones DS. The 50-year legacy of the Harvard report on brain death. *JAMA* 2018;320:335–6.
3. Riishede J, Ethelberg S. Angiographic changes in sudden and severe herniation of brain stem through tentorial incisure. *Arch Neur Psych* 1953;70:399–409.
4. Mollaret P, Goulon M. Le coma dépassé (mémoire préliminaire). *Rev Neurol (Paris)* 1959;101:3–15.
5. Spears W, Mian A, Greer D. Brain death: a clinical overview. *J Intensive Care* 2022;10:1–16.
6. A definition of irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. *JAMA* 1968;205:337–40.
7. Machado C. Brain death: a reappraisal. New York (NY): Springer; 2007.
8. Bernat JL. The whole-brain concept of death remains optimum public policy. *J Law Med Ethics* 2006;34:35–43.
9. Bernat JL. The definition and criterion of death. *Handb Clin Neurol* 2013;118:419–35.
10. Mohandas A, Chou SN. Brain death. A clinical and pathological study. *J Neurosurg* 1971;35:211–8.
11. Wijdicks EF. The neurologist and the Harvard criteria for brain death. *Neurology* 2003;61:970–6.
12. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Defining death: medical, legal, and ethical issues in the determination of death. Washington (DC): US Government Printing Office; 1981.
13. Capron AM. Brain death--well settled yet still unresolved. *N Engl J Med* 2001;344:1244–6.
14. Gardiner D, Shemie S, Manara A, Opdam H. International perspective on the diagnosis of death. *Br J Anaesth* 2012;108 Suppl 1:i14–28.
15. Nguyen D. Evolution of the Criteria of “Brain Death”: A Critical Analysis Based on Scientific Realism and Christian Anthropology. *Linacre Q* 2019;86:297–313.
16. Practice parameters for determining brain death in adults (summary statement). The Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 1995;45:1012–4.
17. Guidelines for the determination of brain death in children. Task Force for the Determination of Brain Death in Children. *Neurology* 1987;37:1077–8.
18. Nakagawa TA, Ashwal S, Mathur M, Mysore MR, Bruce D, Conway Jr, EE, et al. Guidelines for the determination of brain death in infants and children: an update of the 1987 Task Force recommendations. *Crit Care Med* 2011;39:2139–55.
19. Wijdicks EF. Brain death worldwide: accepted fact but no global consensus in diagnostic criteria. *Neurology* 2002;58:20–5.
20. Wijdicks EF. The diagnosis of brain death. *N Engl J Med* 2001;344:1215–21.
21. Pandit RA. Brain death and organ donation in India. *Indian J Anaesth* 2017;61:949–51.
22. Shemie SD, Hornby L, Baker A, et al. International guideline development for the determination of death. *Intensive Care Med* 2014;40:788–97.
23. Wijdicks EF, Varelas PN, Gronseth GS, Greer DM, American Academy of Neurology. Evidence-Based Guideline Update: Determining Brain Death in Adults: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2010;74:1911–8.
24. Shewmon DA. Chronic “brain death”: meta-analysis and conceptual consequences. *Neurology* 1998;51:1538–45.
25. Greer DM, Shemie SD, Lewis A, Torrance S, Varelas P, Goldenberg FD, et al. Determination of Brain Death/Death by Neurologic Criteria: The World Brain Death Project. *JAMA* 2020;324:1078–97.
26. Lewis A, Bernat JL, Blosser S, Bonnie RJ, Epstein LG, Hutchins J, et al. An interdisciplinary response to contemporary concerns about brain death determination. *Neurology* 2018;90:423–6.
27. Lewis A, Greer D. Current controversies in brain death determination. *Nat Rev Neurol* 2017;13:505–9.
28. Greer DM, Kirschen MP, Lewis A, Gronseth GS, Rae-Grant A, Ashwal S, et al. Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Guideline. *Neurology* 2023;101:1112–32.
29. Krawiec C, Mysore MR, Mathur M, Fang X, Zhou S, Thomas NJ, et al. Impact of the Updated Guideline for Pediatric Brain Death De-

- termination on Current Practice. *J Child Neurol* 2022;37:553–61.
30. Wijdicks EF. Pitfalls and slip-ups in brain death determination. *Neurol Res* 2013;35:169–73.
 31. Setta SM, Shemie SD. An explanation and analysis of how world religions formulate their ethical decisions on withdrawing treatment and determining death. *Philos Ethics Humanit Med* 2015;10:6.
 32. Machado C, Kerein J, Ferrer Y, Portela L, de la C Garcia M, Manero JM. The concept of brain death did not evolve to benefit organ transplants. *J Med Ethics* 2007;33:197–200.
 33. Truog RD, Miller FG. The Dead Donor Rule and Organ Transplantation. *N Engl J Med* 2008;359:674–5.
 34. Robertson JA. The dead donor rule. *Hastings Cent Rep* 1999;29:6–14.
 35. Lewis A, Lord AS, Czeisler BM, Caplan A. Public education and misinformation on brain death in mainstream media. *Clin Transplant* 2016;30:1082–9.
 36. Lewis A, Bonnie RJ, Pope T. It's time to revise the Uniform Determination of Death Act. *Ann Intern Med* 2020;172:143–4.
 37. Thomson D, Joubert I, De Vasconcellos K, Paruk F, Mokogong S, Mathivha R, et al. South African guidelines on the determination of death. *S Afr Med J* 2021;111:367–80.
 38. Wahlster S, Wijdicks EF, Patel PV, Greer DM, Hemphill 3rd JC, Carone M, et al. Brain death declaration: practices and perceptions worldwide. *Neurology* 2015;84:1870–9.
 39. Pope TM. Legal briefing: brain death and total brain failure. *J Clin Ethics* 2014;25:245–57.
 40. Verheijde JL, Rady MY, Potts M. Neuroscience and brain death controversies: the elephant in the room. *J Relig Health* 2018;57:1748–63.

This page is intentionally left blank